Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kwong K Wong

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Gynecologic Oncology Research and Practice|May 28, 2016
A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinibMunetaka Takekuma, Kwong K Wong, Robert L Coleman
Gynecologic Oncology|May 28, 2013
Low-grade serous carcinoma: new concepts and emerging therapiesIgnacio Romero, Charlotte C Sun, Kwong K Wong, et al.
Human Pathology|February 10, 2009
Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathwaysAdekunle M Adesina, Dolores Lopez-Terrada, Kwong K Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare TumorDavid M Gershenson, Diane C Bodurka, Karen H Lu, et al.
Gynecologic Oncology|May 23, 2022
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomesDavid M Gershenson, Charlotte C Sun, Shannon N Westin, et al.
Gynecologic Oncology|July 26, 2020
The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistanceLauren P Cobb, Charlotte C Sun, Revathy Iyer, et al.
Molecular Cancer Therapeutics|October 12, 2018
<i>PRKRA</i>/PACT Expression Promotes Chemoresistance of Mucinous Ovarian CancerTakeshi Hisamatsu, Michael McGuire, Sherry Y Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
Targeting aurora kinase with MK-0457 inhibits ovarian cancer growthYvonne G Lin, Anand Immaneni, William M Merritt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2011
Targeting SRC in mucinous ovarian carcinomaKoji Matsuo, Masato Nishimura, Justin N Bottsford-Miller, et al.
Gynecologic Oncology|January 24, 2020
Low-grade serous ovarian cancer: State of the scienceBrian Slomovitz, Charlie Gourley, Mark S Carey, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Gynecologic Oncology Research and Practice|May 28, 2016
A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinibMunetaka Takekuma, Kwong K Wong, Robert L Coleman
Gynecologic Oncology|May 28, 2013
Low-grade serous carcinoma: new concepts and emerging therapiesIgnacio Romero, Charlotte C Sun, Kwong K Wong, et al.
Human Pathology|February 10, 2009
Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathwaysAdekunle M Adesina, Dolores Lopez-Terrada, Kwong K Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare TumorDavid M Gershenson, Diane C Bodurka, Karen H Lu, et al.
Gynecologic Oncology|May 23, 2022
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomesDavid M Gershenson, Charlotte C Sun, Shannon N Westin, et al.
Gynecologic Oncology|July 26, 2020
The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistanceLauren P Cobb, Charlotte C Sun, Revathy Iyer, et al.
Molecular Cancer Therapeutics|October 12, 2018
<i>PRKRA</i>/PACT Expression Promotes Chemoresistance of Mucinous Ovarian CancerTakeshi Hisamatsu, Michael McGuire, Sherry Y Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
Targeting aurora kinase with MK-0457 inhibits ovarian cancer growthYvonne G Lin, Anand Immaneni, William M Merritt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2011
Targeting SRC in mucinous ovarian carcinomaKoji Matsuo, Masato Nishimura, Justin N Bottsford-Miller, et al.
Gynecologic Oncology|January 24, 2020
Low-grade serous ovarian cancer: State of the scienceBrian Slomovitz, Charlie Gourley, Mark S Carey, et al.
Pageof 1